The improved survival of liver transplant recipients (LTRs) has been accompanied by a concomitant rise in long-term liver transplantation complications, including skin cancer. A recent study found that the prevalence of skin cancer among LTRs is 13.5%, a rate equivalent to that observed among kidney transplant recipients. Given the morbidity associated with skin cancer in LTRs, an individualized, multidisciplinary approach to skin cancer prevention that incorporates patient education, encourages consistent use of primary prevention methods, and ensures routine dermatologic screening should be universally adopted in this population. Chemopreventative measures should be considered in LTRs with a high skin cancer burden. Furthermore, additional studies should be performed in order to systematize these recommendations.
DucrouxEBoillotOOcampoMA. Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. Transplantation. 2014;98(3):335–340. doi:10.1097/TP.000000000000051.
2.
UlrichCJürgensenJSDegenA. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161(suppl 3):78–84. doi:10.1111/j.1365-2133.2009.09453.x.
3.
FitzpatrickTB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869–871.
4.
CarencoCFaureSHerreroA. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. Liver Int. 2015;35(6):1748–1755. doi: 10.1111/liv.12758.
5.
Rodríguez-PerálvarezMDe la MataMBurroughsAK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant. 2014;19(3):253–260. doi:10.1097/MOT.000000000000069.
6.
Van SandwijkMSBemelmanFJTen BergeIJ. Immunosuppressive drugs after solid organ transplantation. Neth J Med. 2013;71(6):281–289.
7.
WisemanAC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016;11(2):332–43. doi:10.2215/CJN.08570814.
8.
BurraPBelliLSGinanni CorradiniS. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis. 2017;49(3):241–253. doi:10.1016/dld.2016.12.027.
9.
BlombergMHeSYHarwoodC. Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017;177(5):1225–1233. doi:10.1111/bjd.15950.
10.
WulfHCPavelSStenderIBakker-WensveenCA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86(1):25–28.
11.
BergDBubJChristensonLOtleyCSalascheSStaskoT. Skin Cancer in Organ Transplant Recipients: A Downloadable Lecture for Health Care Providers. International Transplant Skin Cancer Collaborative. http://www.itscc.org/members/. Accessed 3.30.18.
JirakulapornTEndrizziBLindgrenBMathewJLeePKDudekAZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant. 2011;25(4):541–548. doi: 10.1111/j.1399-0012.2010.01348.x.
17.
BavinckJNTiebenLMVan der WoudeFJ. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933–1938.
18.
UlrichCJohannsenARöwert-huberJUlrichMSterryWStockflethE. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20(4):482–488.
19.
DragoFCiccareseGCogornoLCalviCMarsanoLAParodiA. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study. Eur J Dermatol. 2017;27(4):382–385.
20.
EuvrardSMorelonERostaingL. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–339.
